» July 2010: Inhalation Technology Progress Report
Respiratory diseases, from infections to obstructive lung disease to cancer, are major public health problems. Acute respiratory infections are the third largest cause of death worldwide. The goal of the Inhalation Technology Program is to develop technologies to facilitate inhalation therapy that will help reduce human suffering and eventually health care costs.
The program will apply inhalation technology to the diagnosis and treatment of both acute and chronic respiratory and non-respiratory ailment. The respiratory tract can be used for not only local delivery but also as a conduit to deliver therapeutic agents systemically for the treatment of non-respiratory diseases. The respiratory tract can also provide a “window” for monitoring biomarkers of disease states.
Areas for innovation will include use of novel combinations of gases, therapeutic agents, inhalation systems, delivery systems, “smart-delivery” or self-monitoring/dosing devices.
The prevalence of respiratory diseases is among the leading causes of human suffering and death in the world. Most noteworthy are acute respiratory infections (the third largest cause of death worldwide), chronic obstructive pulmonary disease, or “COPD” (fourth largest cause of death worldwide), followed by other chronic conditions such as asthma, respiratory distress syndrome, sleep apnea, cystic fibrosis, and tuberculosis, as well as lung cancers and pulmonary vascular disorders such as pulmonary hypertension and pulmonary embolism.
The increasing incidence of respiratory diseases, coupled with their chronic nature, and the increase in expected life span in most modern societies, translates into higher prevalence, disability, and increasing costs to society (cost of hospitalization and treatment, work days lost, premature death). Many respiratory diseases require lifelong medical treatment.
It is the premise of the CIMIT Inhalation Technology Program that developing technologies to facilitate treatment of respiratory disease and to deliver therapy through an inhaled route for systemic therapy will help to reduce human suffering and eventually health care costs.
CIMIT’s Inhalation Technology Program is focused on developing novel inhalation technologies to treat respiratory and non-respiratory diseases. The goal is to establish a world-leading platform for research and development of technologies and techniques that use the respiratory tract for the delivery of therapy for local lung disease and as a “highway” to deliver agents systematically.
Areas for innovation will include use of novel combinations of gases, therapeutic agents, inhalation systems, delivery systems, “smart-delivery” or self-monitoring/dosing devices. Multidisciplinary innovations hold particular promise.
Specific aims of the Inhalation Technology Program include:
Initial research priorities for 2009 include application of inhalation technologies for organ protection and critical care, respiratory and infectious diseases and oncology.
Specifically, organ protection in the acute clinical settings should focus on problems such as cerebral ischemia, sepsis & inflammation, suspended animation, traumatic injury including brain hypertension emergencies and intra-operative organ protection. Ideal agents could be delivered by closed loop monitoring to provide organ protection or diagnose injury.
Respiratory/infectious disease treatment or prevention can take place in acute or ambulatory settings. There is vast clinical need for improved delivery in asthma, COPD and pulmonary hypertension. Potential projects include optimizing of delivery of therapeutic agents, regional targeting of inhalation agents, and monitoring for safety, frequency of use, and patient compliance.
In the area of oncology, the pulmonary highway may be an appropriate route of inhalation agents in acute and ambulatory settings for pain relief, diagnosis, or treatment with lower toxicity.
FY 2011 & 2010 CIMIT-Funded
Inhalation Technology Projects
|YEAR||PRINCIPAL INVESTIGATOR||INSTITUTION||PROJECT TITLE|
|2011||Jussi Saukkonen, MD||Boston University||Low-Cost, Low Maintenance Mechanical Ventilator for Developing World or Mass Casualty|
|2011||Yang (Ted) Teng, MD, PhD||Brigham and Women's Hospital||Carbon monoxide mediated neural protection for treating spinal cord injury|
|2010||Elazer Edelman, MD, PhD||Massachusetts Institute of Technology||Tissue Engineering Therapies for Inhalation Injury|
|2010||Malay Mazumder, PhD||Boston University||Electrostatic Dry Powder Inhaler for Constant Dose Respiratory Drug Delivery|
Past CIMIT-Funded Science Projects Relevant to Inhalation Technology
|YEAR||PRINCIPAL INVESTIGATOR||INSTITUTION|| CIMIT PROGRAM AREA
& PROJECT TITLE
|2008||Homer Pien||MGH, Draper, BU||Image Guided Therapy: A Multidisciplinary Approach to Improving Perfusion Imaging|
|2008, 2006||Bruce Levy||BWH||Clinical Systems Innovation: Remotely Monitored Inhaler to Predict and Prevent Asthma Attacks|
|2007||George Washko||BWH||Image Guided Therapy: Quantitative Analysis of Airways and Airspace Disease Visualized on Computer Tomographic Imaging in Subjects with COPD|
|2006||Yandong Jiang||MGH||Clinical Systems Innovation: A Novel Negative Pressure Ventilation System|
|2006||Malinda Tupper||Draper||Biodetection & Sepsis Control: Novel Clinical Diagnostics Using Differential Mobility Spectrometry and Bioinformatics|
|2005||Massimo Ferrigno||MGH||Trauma & Casualty Care: Warming Hypothermic Patients Through the Respiratory System During Medical Evacuation|
|2004||Cristina Davis||Draper||Biodectection & Sepsis Control: Non-Invasive Breath Analysis|
|2004, 2003||Bob Kacmerek||MGH||Trauma & Critical Care: Assessment of Portable Ventilators|
|2003||Massimo Ferrigno||MGH||Trauma & Casualty Care: Field Cooling of Injured Soldiers|
|2003||Angela Zapata||Draper||Biodectection & Sepsis Control: Detection of Pentane in Patient Exhaled Breath by FAIMS|
|1999||Edward Ingenito||BWH||MIS: Lung volume reduction|
Other CIMIT Work Relevant to
|INVESTIGATORS||INSTITUTION / ORGANIZATION||SCIENCE PROGRAM & WORK||DATE|
U of Pitt
|Inhalation Technology and Trauma & Casualty Care: BAA - Inhaled Carbon Monoxide for Treatment of Hemorrhage and Tissue Injury||2008 - TBD|
|Jussi Saukkonen||BUMC, BVAMC||Inhalation Technology: BAA - Xenon based TBI treatment||2008 - TBD|
Penny Ford Carleton
|MGH||Clinical Systems Innovation: Wearable monitor with respiratory and arrhymia-detection sensors||2008|
|MGH||Inhalation Technology: BAA - Negative Pressure Ventilation and Resuscitation||2008 - TBD|
|Bill Weisman||Harvey Mudd College, Biostar||Trauma & Casualty Care: Design and production of a Self-Operating Closed-Loop Ventilator System||2007|
Inhalation Technology Program at the
CIMIT Forum and Past Events
|CIMIT Inhalation Technology Consortium Meeting
CIMIT Summer Education Series 2009: Frontiers of Inhalation Technologies in Biomedical Sciences and Clinical Medicine
Jul. 7, 2009
Joseph Brain, SD:
Harvard School of Public Health
Anthony J. Hickey, PhD, DSc:
University of North Carolina
Philippe Richebe, MD, PhD: University of Washington
Elazer Edelman, MD, PhD:
Reinhard Vehring, PHD: Pearl Therapeutics
Design of Structured Microparticles for Inhalation
|Forum: Inhalation Technology||Feb. 3, 2009||
Warren M. Zapol, MD:
Myrna Dolovich, P ENG:
Augustine MK Choi, MD
News & Press Releases
OptiNose joins CIMIT ILP